Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Free Cash Flow (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Free Cash Flow data on record, last reported at -$6.1 million in Q3 2025.

  • For Q3 2025, Free Cash Flow rose 67.26% year-over-year to -$6.1 million; the TTM value through Sep 2025 reached -$66.1 million, up 35.31%, while the annual FY2024 figure was -$80.2 million, 37.49% up from the prior year.
  • Free Cash Flow reached -$6.1 million in Q3 2025 per FBIO's latest filing, up from -$27.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.1 million in Q3 2025 and bottomed at -$47.9 million in Q4 2022.
  • Average Free Cash Flow over 5 years is -$29.7 million, with a median of -$27.6 million recorded in 2025.
  • Peak YoY movement for Free Cash Flow: plummeted 111.76% in 2022, then soared 67.26% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$40.7 million in 2021, then decreased by 17.91% to -$47.9 million in 2022, then rose by 27.06% to -$35.0 million in 2023, then soared by 63.08% to -$12.9 million in 2024, then surged by 52.66% to -$6.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$6.1 million in Q3 2025, -$27.6 million in Q2 2025, and -$19.6 million in Q1 2025.